By Fineline Cube Mirxes Holding Company Ltd, a Singapore‑headquartered RNA technology company, announced a strategic partnership with N Health, a healthcare solutions provider and member of Bangkok Dusit Medical Services (BDMS) Group, to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. The collaboration will deploy Mirxes’ GASTROClear (gastric cancer) and LUNGClear (lung cancer) tests across nearly 60 hospitals in the N Health network, creating a scalable model for early disease detection in Thailand and Southeast Asia.
Partnership Overview
| Item | Detail |
|---|---|
| Companies | Mirxes Holding Company Ltd, N Health (BDMS Group member) |
| Technology | microRNA (miRNA) cancer screening |
| Products | GASTROClear (gastric cancer), LUNGClear (lung cancer) |
| Market | Thailand (initial), Southeast Asia (expansion) |
| Network Reach | ~60 hospitals within N Health network |
| Strategic Goal | Scalable early cancer detection model |
Technology Profile: miRNA Screening
Mechanism: Mirxes’ platform detects circulating microRNA biomarkers in blood, enabling non‑invasive, high‑sensitivity detection of gastric and lung cancers at early stages when treatment outcomes are significantly improved.
GASTROClear: Validated for gastric cancer screening with >85% sensitivity and specificity, addressing Asia’s highest gastric cancer incidence region.
LUNGClear: Targets lung cancer detection, critical for Thailand’s smoking‑related cancer burden and air pollution exposure risks.
Market Significance: First miRNA‑based cancer screening platform entering Thailand’s healthcare system, offering cost‑effective alternative to endoscopy and CT imaging for high‑risk populations.
Market Opportunity
Thailand Cancer Burden:
- Gastric Cancer Incidence: ~10,000 new cases annually, 50% diagnosed at late stage
- Lung Cancer Incidence: ~25,000 new cases annually, 70% present at advanced stage
- Screening Gap: <20% of high‑risk individuals undergo regular screening due to cost and access barriers
Market Size:
- Thailand Cancer Screening Market: ¥3‑4 billion (US$420‑560 million) in 2025, growing at 12% CAGR
- miRNA Sub‑segment: ¥500‑800 million opportunity by 2030
- Southeast Asia Expansion: ¥2‑3 billion additional market potential across Indonesia, Malaysia, Vietnam
BDMS Network Advantage: N Health’s 60‑hospital network provides immediate market access to urban and regional centers, accelerating adoption and reimbursement pathways.
Financial Implications
Revenue Model:
- Test Pricing: Projected ¥1,500‑2,000 per miRNA test (vs. ¥5,000‑8,000 for endoscopy/CT)
- Volume Trajectory: 100,000‑150,000 tests annually by 2027, scaling to 500,000 by 2030
- Revenue Potential: ¥150‑300 million (US$21‑42 million) for Mirxes by 2028
Partnership Economics: Revenue‑sharing model with N Health likely 60/40 (Mirxes/N Health), given technology ownership vs. distribution network.
Platform Validation: Thailand partnership de‑risks Mirxes’ global expansion strategy, following successful launches in Singapore and Japan.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Mirxes’ market penetration, revenue forecasts, and partnership expansion in Southeast Asia. Actual results may differ materially due to regulatory approvals, reimbursement negotiations, competitive responses, and market adoption rates.-Fineline Info & Tech